RE: Retest of 350 p/4 euro14 May 2020 14:15
LIKE THIS PART OF RNS
Sales, orders and commitments to purchase the test since the initial launch have significantly exceeded expectations and have been transformational for the Group; all indications are that the positive financial effects of this will continue. This is additional revenue to Novacyt's other operations at Primerdesign and Lab21 Products. The Directors believe the significant demand for the Company's COVID-19 test will continue through to the end of the year, and may extend well into 2021, as the global demand for COVID-19 testing continues to increase. Further revenues are also expected from the launch of the
Company's COVID-19 related products described later, which include the Exsig™ Direct extraction reagent and mobile
COVID-19 testing
SOME NICE BUYS
5000 share buy
3000 share buy